A61K 39/05
Actinobacteria
Official title: {Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella}, Corynebacterium; Propionibacterium {(Mycobacterium A61K39/04)}
A61K39/05 (Actinobacteria) appears on 212 US grants and 316 published applications in this corpus.
Search patents in A61K- Granted patents
- 212
- Published applications
- 316
- Assignees
- 192
- Inventors
- 617
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 3 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 3 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 2 | 0 |
| 1998 | 4 | 0 |
| 1999 | 5 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 1 |
| 2002 | 2 | 6 |
| 2003 | 2 | 8 |
| 2004 | 3 | 8 |
| 2005 | 3 | 9 |
| 2006 | 1 | 7 |
| 2007 | 3 | 5 |
| 2008 | 5 | 9 |
| 2009 | 4 | 19 |
| 2010 | 2 | 13 |
| 2011 | 3 | 14 |
| 2012 | 4 | 14 |
| 2013 | 8 | 17 |
| 2014 | 15 | 21 |
| 2015 | 11 | 21 |
| 2016 | 12 | 20 |
| 2017 | 12 | 15 |
| 2018 | 22 | 14 |
| 2019 | 13 | 13 |
| 2020 | 11 | 15 |
| 2021 | 14 | 19 |
| 2022 | 6 | 12 |
| 2023 | 12 | 10 |
| 2024 | 5 | 14 |
| 2025 | 7 | 6 |
| 2026 | 2 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Transient expression of biologic materials17 Mar 2026US 12,576,041 B1
- Glycosylated comp pilin variants, methods of making and uses thereof17 Mar 2026US 12,577,280 B2Vaxnewmo LLC
- Nanoparticles for use in redirection against the tumour of a non-tumour specific immune response, based on a pre-existing immunity30 Dec 2025US 12,508,310 B2Pharmaexceed S.R.L.
- Compositions for use in treatment of acne23 Dec 2025US 12,502,424 B2Sanofi Pasteur Limited
- Phage-derived particles for in situ delivery of DNA payload into C. acnes population4 Nov 2025US 12,460,216 B2Eligo Bioscience
- Compositions for use in treatment of acne13 Aug 2026US 2026/0232783 A1Sanofi Pasteur Limited
- Cutibacterium acnes recombinant phages, method of production and uses thereof6 Aug 2026US 2026/0226484 A1Eligo Bioscience
- Shigella multiple antigen presenting immunogenic composition and fusion proteins thereof28 May 2026US 2026/0144857 A1Children's Medical Center Corporation
- Phage-derived particles for in situ delivery of dna payload into c. acnes population23 Apr 2026US 2026/0109991 A1Eligo Bioscience
- Diphtheria-tetanus-pertussis compound adjuvant combined vaccine16 Apr 2026US 2026/0102480 A1Changchun BCHT Biotechnology Co.
Most cited
By later US patents
- Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery242US 6,060,082 AMassachusetts Institute of Technology · 2000
- Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response90US 6,797,276 B1The United States of America as represented by the Secretary of the Army · 2004
- Adjuvant incorporation in immunonanotherapeutics87US 8,637,028 B2Massachusetts Institute of Technology · 2014
- Vaccine compositions and method for induction of mucosal immune response via systemic vaccination73US 5,518,725 AUniversity of Utah Research Foundation · 1996
- Multiple vaccination including serogroup C meningococcus62US 8,444,992 B2Novartis Vaccines and Diagnostics, Inc. · 2013